Intervention

Mepolizumab

ClinicalTrials.gov intervention label

Clinical trials38

Recruiting2

Common conditions21

Lead sponsors shown15

Clinical trials

38 shown

Real Life Study of Biologicals in Patients With Severe CRSwNPNCT05938972 · 2022-03-01

Residual Exacerbations With MepolizumabNCT04578171 · 2021-07-06

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive StudyNCT06041386 · 2024-03-20

ACTIVE_NOT_RECRUITING

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab TreatmentNCT05642806 · 2023-07-01

Response and Remission to Treatment With Anti-IL5/IL5R AntagonistsNCT06348173 · 2023-06-01

Blood Leukocyte Profiling in Eosinophilic Type 2 Asthma: Influence of Systemic IL-5 TargetingNCT05689931 · 2023-02-01

Study for Children & Adolescent With Severe Asthma With an Eosinophilic Phenotype Treated With MepolizumabNCT05139381 · 2022-03-02

Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways DiseasesNCT04765722 · 2021-12-14

Nation-wide Health Resource Consumption and Costs Associated With MepolizumabNCT04550780 · 2021-12-03

Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic AsthmaNCT05063981 · 2021-11-25

Mepolizumab Effectiveness in Severe Eosinophilic Asthma and BronchiectasisNCT05189613 · 2021-09-01

Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)NCT04823585 · 2021-08-12

Evaluation of Volatile Organic Compounds in Mepolizumab TherapyNCT04924478 · 2021-07-01

Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic AsthmaNCT04276233 · 2021-06-29

Impulse Oscillometry Measurements in Severe Eosinophilic Asthmatics Before and After Anti-IL-5 Factor InitiationNCT05147155 · 2021-04-19

Similarities and Differences of Biological Therapies for Severe Asthma.NCT04665141 · 2021-04-07

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypeNCT04718389 · 2021-01-26

Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic TrialNCT04075331 · 2020-09-07

Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic AsthmaNCT04512521 · 2020-05-04

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelNCT04133909 · 2019-10-30

Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".NCT04585997 · 2018-11-03

A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban ChildrenNCT03292588 · 2017-11-07

Study of Mepolizumab Autoinjector in AsthmaticsNCT03099096 · 2017-05-04

Study of Mepolizumab Safety Syringe in AsthmaticsNCT03021304 · 2017-02-01

Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic AsthmaNCT03453021 · 2016-01-25

Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY StudyNCT02594332 · 2015-11-17

Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in ChildrenNCT02377427 · 2015-08-25

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma ControlNCT02281318 · 2014-12-11

A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic SubjectsNCT02135692 · 2014-05-29

Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)NCT02105961 · 2014-04-24

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT02105948 · 2014-04-15

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic SubjectsNCT01842607 · 2013-05-27

Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory AsthmaNCT01691508 · 2012-10-01

MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic SubjectsNCT01691859 · 2012-09-28

Mepolizumab Treatment for Rhinovirus-induced Asthma ExacerbationsNCT01520051 · 2012-01-01

Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic BronchitisNCT01463644 · 2012-01-01

Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated EosinophilsNCT01366521 · 2011-02-01

This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With HypereosinophilicNCT00244686

NO_LONGER_AVAILABLE

Common conditions

Leading sponsors

GlaxoSmithKline16 McMaster University2 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1 Clinica Universidad de Navarra, Universidad de Navarra1 Hannover Medical School1 Helsinki University Central Hospital1 Istituti Clinici Scientifici Maugeri SpA1 Johannes Gutenberg University Mainz1 King's College Hospital NHS Trust1 Laval University1 National Institute of Allergy and Infectious Diseases (NIAID)1 Policlinico Universitario, Catania1 Region Skane1 St. Paul's Sinus Centre1 Université de Montréal1

Trial status mix

COMPLETED24

UNKNOWN9

RECRUITING2

ACTIVE_NOT_RECRUITING1

NO_LONGER_AVAILABLE1

TERMINATED1

Phase mix

PHASE315

PHASE46

PHASE24

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.